Skip to main content
. 2023 Nov 28;13:20941. doi: 10.1038/s41598-023-47765-7

Table 1.

Clinical, radiological and biochemical data of the study population.

Total (n = 30) 3-month mRS 0–2 (n = 10) 3-month mRS 3–6 (n = 20) p-value
Females/males 17/13 5/5 12/8 0.602
Age (years) 75.1 (± 11.3) 75.5 (± 9.4) 75.0 (± 12.4) 0.974
Time from onset to blood sampling 22 h 40 m (18 h 45 m–23 h 04 m) 20 h 53 m (15 h 38 m–24 h 8 m) 23 h 30 m (19 h 30 m–27 h 30 m) 0.140
Previous neurological diseases* (yes/no) 5/25 2/8 3/17 0.729
ASPECTS at admission 7 (7–8) 9 (7.5–9) 7 (6–8) 0.015
NIHSS at admission 14.0 (10.0–17.0) 13.0 (8.8–16.3) 14.0 (10.3–17.0) 0.656
Thrombectomy (yes/no) 27/3 9/1 18/2 1.00
Intravenous thrombolysis (yes/no) 11/19 5/5 6/14 0.284
ASPECTS after 24–72 h 7 (5–8) 7.5 (7–8.75) 6.5 (5–7) 0.061
NIHSS score change within 24 h 3 (− 2.5 to 9) − 1 (− 3.75 to 3) 9 (7.5–12.3) 0.0001
24 h NIHSS 10.0 (4.3–14.8) 1.5 (0.8–6.3) 12.5 (8.3–21.5)  < 0.0001
48 h NIHSS 9.0 (1.0–14.0) 0.5 (0.0–4.0) 11.0 (9.0–22.0)  < 0.0001
72 h NIHSS 6.0 (1.0–14.0) 1.0 (0.0–3.3) 12.0 (6.0–26.0)  < 0.0001
NIHSS at discharge 3.0 (1.0–7.8) 0.5 (0.0–2.5) 7.5 (2.5–13.3) 0.0005
mRS at discharge 4.0 (1.3–5.8) 1.0 (1.0–2.5) 5.0 (4.0–6.0)  < 0.0001
mRS after 90 days 4.0 (1.3–6.0) 1.0 (1.0–2.3) 5.5 (4.0–6.0)  < 0.0001
Creatinine (mg/dl) 0.855 (0.740–1.213) 0.915 (0.773–1.060) 0.815 (0.710–1.250) 0.860
β-syn (pg/ml) 20.1 (5.8–43.8) 4.8 (1.9–25.1) 32.6 (9.2–94.4) 0.0023
NfL (pg/ml) 50.4 (34.0–113.1) 34.4 (19.3–49.8) 76.6 (42.1–178.8) 0.0011
GFAP (ng/ml) 6.3 (1.0–20.5) 0.5 (0.2–7.1) 9.2 (5.3–21.8) 0.0045

Age is reported as mean ± standard deviation, other continuous variables as median (interquartile range).

*1 dementia, 1 Parkinson’s disease, 1 previous stroke, 2 delirium.